OncoCyte Analyst Ratings
OncoCyte's Strategic Initiatives and Financial Health Garner Buy Rating
OncoCyte Analyst Ratings
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
OncoCyte Analyst Ratings
OncoCyte Analyst Ratings
BTIG Reaffirms Their Hold Rating on OncoCyte (OCX)
Piper Sandler Maintains Neutral on OncoCyte, Lowers Price Target to $3
OncoCyte Analyst Ratings
OncoCyte (OCX) Gets a Hold From Piper Sandler
OncoCyte Analyst Ratings
Benchmark Maintains Speculative Buy on OncoCyte, Lowers Price Target to $5
OncoCyte Analyst Ratings
OncoCyte Analyst Ratings
OncoCyte Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), OncoCyte (OCX)
Needham Trims Price Target on OncoCyte to $0.45 From $1.40, Keeps Buy Rating
Needham Maintains Buy on OncoCyte, Lowers Price Target to $0.45
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), PepGen Inc. (PEPG) and OncoCyte (OCX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Nyxoah (NYXH), Miromatrix Medical (MIRO) and OncoCyte (OCX)
No Data